Further,potential promising future perspectives for the treatmentof HCC are discussed.vip世界肝病学杂志:英文版(电子版)ErikSlottaOttoKollmarVolkerEllenriederMichaelGhadimiHomayounfar.Slotta, J.E., Kollmar, O., Ellenrieder, V., Ghadimi, B.M., Homayounfar, K., 2015. Hepatocellular carcinoma: Surgeon...
Tailored therapies based on tumor biology are needed to improve treatment response and ultimately patient survival. 展开 关键词: hepatocellular carcinoma living donor liver transplant resection therapy DOI: 10.1097/MOG.0b013e3282fafef3 被引量: 44 ...
hepatocellular carcinoma; systemic therapy; molecular targeted therapy; immune checkpoint inhibitor1. Introduction Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction of the molecular targeted agent, sorafenib in 2007. Although sorafenib expanded the treatment ...
HBV Cure MeetingOverview of HBV Functional Cure Virological & Immunological Insights into Functional Cure Biomarker forum Invited Pharma Presentations and Free Papers Saturday, 23 August 2025 SHC Main ConferenceHepatocellular carcinoma Advanced Liver Disease ...
Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction of the molecular targeted agent sorafenib in 2007. Although sorafenib expanded the treatment options for extrahepatic spread (EHS) and vascular invasion, making long-term survival of patients with advanced di...
Hepatocellular carcinoma-JapanPⅠb 「Halaven」(eribulin/E7389) Anticancer agent / microtubule dynamics inhibitor In-house Injection Monotherapy (Additional Formulation) Liposomal formulation-JP/EUPⅠ In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formula...
The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatohepatitis, updated guidelines on the screening, diagnosis and treatment of MASLD, and liver stiffness measu...
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma. T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC Jonah Feldman September 20th 2024 Trastuzumab deruxtecan improved time to deterioration...
Chemotherapy is a treatment used to kill cancer cells. It involves taking one or more of a type of drug that interferes with the DNA of fast-growing cells. These drugs are subdivided into specific classes such as alkylating agents, antimetabolites, anthracyclines and topoisomerase inhibitors. ...
Dr. Raj Chovatiya shares his thoughts on the recent approval of ruxolitinib for treatment of vitiligo and where he might use it, either alone or in combination with other vitiligo treatments.Play Video Now Viewing EP. 1: Latest Advances in the Management of Vitiligo Raj Chovatiya, MD, PhD:...